Stock Profiler is pleased to introduce HearAtLast Holdings, Inc. (PINKSHEETS: HRAL) to the investment community. Please visit us at www.stockprofiler.us for more detailed information.

-------------------------------------------

HearAtLast Holdings, Inc. closed at $0.056 Monday, trading 478,757 shares.

Company News- November 2, 2009: HearAtLast Amends Q2 Financials and Reports 53% Year Over Year Reduction in Operating Expenses

(PINKSHEETS: HRAL) HearAtLast Holdings, Inc. announced yesterday that the Company has posted its amended earnings report on pinksheets.com. The posted earnings reflect the fiscal second quarter period covering 04/01/2009 - 06/30/2009.

http://smallcapvoice.com/blog/8-26-09-audio-interview-with-hearatlast-holdings-inc-otcpk-hral/

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About HearAtLast

HearAtLast Holdings, Inc. is a Nevada corporation that owns and operates its wholly owned subsidiary of hearing stores co-located within select Wal-Mart stores throughout Canada. Their chain of hearing stores specializes in the sale of digital hearing aids and testing services. The Company is the affordable hearing solution for Canadians, combining the most sought after retail space in North America with convenience and location. For more information please visit www.hearatlast.com.

-------------------------------------------

Competitive Technologies, Inc. closed at $2.13 Monday, trading 72,861 shares.

Company News- November 3, 2009: Competitive Technologies Booking Revenue From Worldwide Shipments of Pain Therapy Medical Devices

Competitive Technologies, Inc. (NYSE Amex:CTT) announced earlier today that it is moving forward with its plan to restore profitability. Its Calmare Therapy Treatment*, pain therapy medical device is treating patients in several locations worldwide. Revenue for product shipments has been recorded for shipments made during the fiscal quarter ended October 31, 2009.

To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.

-------------------------------------------

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. AssociatesFortune.com is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.fastmoneytalk.com, www.markettelegraph.com, www.thewallstreetleader.com and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.

Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL, Businesswire, PR Newswire Alphatrade, Comtex, Comtex A, Comtex B, Zacks, Real Trader, Market Wire, Market News Publications, AFX U.K., Future World, JAGNotes.com, Internetwire, EURO PR News, First Call, PrimeZone, U.S. News, Forbes, Track Notes, Hearing Loss, Hearing Aids, Medical Devices, Wal-Mart

CONTACT: AssociatesFortune.com e-mail: info@stockprofiler.us WWW: http://www.associatesfortune.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

"We are honored that our innovative Calmare Therapy Treatment has been recognized by this prestigious group in our home state of Connecticut," said Mr. Nano. "With all the negative press about narcotic painkillers, it is incredibly rewarding to be able to provide this non-invasive, effective relief for intense pain. Being acknowledged by this organization helps us to reach a large audience of individuals suffering pain and in need of palliative care.

"We have FDA 510(k) clearance and CE Medical Device approval for our Calmare Therapy Treatment and are starting to see accelerated global sales of the device. We are looking forward to working with more physicians and medical clinicians to provide relief to the millions worldwide who suffer from debilitating neuropathic pain."

U.S-based clinical studies are underway at several prestigious university medical centers, including the Virginia Commonwealth University Massey Cancer Center, the University of Miami Pain Management Center, and the University of Wisconsin-Madison Carbone Cancer Center. In May 2009, clinical investigators at the Massey Cancer Center began an independent clinical study to examine the ability of CTT's Calmare Therapy Treatment to decrease pain associated with chemotherapy-induced peripheral neuropathy (CIPN), which can be difficult to treat with traditional methods. Early results from the Massey study are quite promising.

"Pain therapy treatment has become high priority at Europe's largest university, La Sapienza of Rome, as well," added Mr. Nano. "La Sapienza, together with the Fondazione Parco Biomedico San Raffaele of Rome, has established a new medical school dedicated to the treatment of pain. Our Calmare Therapy Treatment will be a major component of the new medical school's program. La Sapienza, founded in 1303, is the largest university in Europe with over 145,000 students, including three other medical schools with 7,000 beds."

"Our Calmare Therapy Treatment completely avoids the harmful, potentially fatal, adverse side effects and addictive properties linked to narcotic painkillers," said Aris Despo, CTT's Executive VP, Business Development. "The CDC's National Center for Health Statistics reported last month that the number of fatal poisonings involving opioid analgesics more than tripled from 1999 to 2006, largely due to the increased use of these powerful narcotic painkillers. In that same period, deaths from opioid poisoning overtook traffic fatalities as the largest cause of injury-related deaths in 16 states, including our home state of Connecticut. One opioid analgesic, hydrocodone, topped the AARP Bulletin's "50 Most Prescribed Drugs" list, with over 121 million prescriptions written in 2008, nearly double the number of prescriptions for the next drug on the list. There are no such risks with our Calmare Therapy Treatment."

CTT has exclusive worldwide rights to the Calmare Therapy Treatment device, which was developed in Italy by CTT's client, Prof. Giuseppe Marineo. The Calmare Therapy Treatment has been used to treat more than 3,000 patients in Europe and the US. CTT partner GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution. For more information about the device, visit www.CalmareTT.com.

About The Connecticut Quality Improvement Partnership, Inc.

The Connecticut Quality Improvement Partnership, Inc., founded in 1987, is America's first state-level quality award using the Malcolm Baldrige National Quality Award for Performance Excellence Criteria in an effort to advance innovative programs that improve quality, performance, and marketplace competitiveness in Connecticut organizations. For more information, visit the CQIA website: www.ctqualityaward.org/.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

(Photo: http://www.primezone.com/newsroom/prs/?pkgid=)

* The Calmare Therapy Treatment uses Competitive Technologies' MC-5A pain therapy medical device to provide rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other narcotic painkillers.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Competitive Technologies, Inc.

CONTACT:  IR Services, LLC
Johnnie D. Johnson
860 434 2465
jdjohnson@corpirservices.com

"The global pain management market generated $46.5 billion in sales in 2007, a 12.5% increase over 2006, according to a report published in June of 2009. Globally, pain treatment is coming to the forefront of medical care. For physicians, the ability to help patients with debilitating pain using our non-invasive medical device is an attractive alternative to powerful narcotics. The Calmare Therapy Treatment completely avoids the harmful adverse side effects and addictive properties, with risk of death, linked to narcotic painkillers.

"I am confident that global sales will increase dramatically in fiscal 2010," Mr. Nano continued. "With FDA 510(k) clearance and CE Medical Device approval, sales in the U.S., Europe, and other parts of the globe have accelerated. We currently have distribution agreements in place for over 40 countries, representing over 50% of the world's population, including our newest distributor for sales in Greece and Cyprus. Our Geneva, Switzerland-based distributor Life Episteme Group recently ordered 50 devices, and in the U.S., Rhode Island-based Calmar Pain Relief placed an order this month for 20 devices."

U.S-based clinical studies are underway at several prestigious university medical centers, including the Virginia Commonwealth University Massey Cancer Center, the University of Miami Pain Management Center, and the University of Wisconsin-Madison Carbone Cancer Center. In May 2009, clinical investigators at the Massey Cancer Center began an independent clinical study to examine the ability of CTT's Calmare Therapy Treatment to decrease pain associated with chemotherapy-induced peripheral neuropathy (CIPN), which can be difficult to treat with traditional methods. Early results from the Massey study are quite promising.

The company continues to move in the right direction toward restoring profitability. Management has been diligent about reducing costs and fully expects revenue to grow as sales for the pain therapy medical device and other technologies in the portfolio increase. Strategic actions have decreased expenses over 45% since last year, decreasing from $7.2 million to approximately $3.8 million, reflecting further staff reductions and other cost-cutting measures. Revenue for the year was $0.35 million, compared to $1.2 million for the prior fiscal year. The decrease in revenue was primarily due to lower royalties from both our homocysteine assay and sexual dysfunction technology. Net loss for the full year was $3.5 million or $0.40 per share, compared to a net loss of $6.0 million, or $0.73 per share for the prior year.

An agreement signed in August 2009 with Fusion Capital Fund II, LLC, provides CTT with the option, if needed, to obtain up to $8 million in additional working capital from sales of common stock which could be used for targeted marketing and sales development of high profit potential technologies, including the pain therapy medical device. "Our focus in calendar 2009 and 2010 is to get the Calmare Therapy Treatment more broadly established in the marketplace and aggressively drive sales," said Nano. "When the marketing and distribution mechanisms are firmly in place, we will shift our focus to further developing and commercializing our portfolio of other technologies, including our nanotechnology bone biomaterial, our sexual dysfunction and obesity treatment technologies, a skin-pigment enhancer being researched as a skin cancer preventative, and several innovative technologies currently under evaluation."

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

* The Calmare Therapy Treatment uses Competitive Technologies' MC-5A pain therapy medical device to provide rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other narcotic painkillers.

                    COMPETITIVE TECHNOLOGIES, INC.

               FOURTH QUARTER AND FULL YEAR FISCAL 2009

             CONDENSED CONSOLIDATED RESULTS OF OPERATIONS
           (dollars in thousands, except per share amounts)


                                Fourth Quarter       Fiscal Year
                                Ended July 31,      Ended July 31,
                                2009      2008      2009      2008
                               -------   -------   -------   -------


 Revenue                       $    48   $   225   $   348   $ 1,194

 Operating expenses                870     1,322     3,828     7,160

 Provision for income tax           --        --        --        --
                               -------   -------   -------   -------

 Net (loss)                    $  (822)  $(1,097)  $(3,480)  $(5,966)
                               =======   =======   =======   =======

 Net (loss) per share:
   Basic and diluted           $  (.09)  $ (0.13)  $  (.40)  $ (0.73)
                               =======   =======   =======   =======

 Weighted average number of
  common shares outstanding:
   Basic and diluted (000)       9,500     8,180     8,740     8,156


                                                     At        At
                                                   July 31,  July 31,
                                                    2009      2008
                                                   -------   -------
 Other Financial Data
   Cash and cash equivalents                       $   752   $ 2,237
                                                   =======   =======
   Total assets                                    $ 1,401   $ 3,111
                                                   =======   =======

   Total liabilities                               $ 1,116   $ 1,518
                                                   =======   =======
   Shareholders' equity                            $   285   $ 1,593
                                                   =======   =======

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Competitive Technologies, Inc.

CONTACT:  IR Services, LLC
Johnnie D. Johnson
860 434 2465
jdjohnson@corpirservices.com

Calmar will also furnish CTT's MC-5A pain therapy medical device to other medical doctors who will open pain therapy treatment centers in selected U.S. cities. The agreement calls for Calmar to purchase a minimum of 20 of CTT's pain therapy medical devices with an estimated retail value of approximately $1 million over the next 14 months. The agreement also allows Calmar to purchase an additional 38 devices by November 2011, with an estimated retail value of approximately $2 million.

This non-invasive technology brings CTT to the forefront in meeting the needs of patients and improving palliative healthcare globally. CTT has exclusive worldwide rights to the device, which has U.S. FDA clearance for sales in the U.S. as well as Medical Device CE certification from the E.U. Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the device has been used to treat over 3,000 patients in Europe and the US. CTT partner, GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution. Distribution agreements are in place in 42 countries around the world, accounting for more than 50% of the world's population. For more information on the device, visit www.CalmareTT.com.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

http://www.financialwire.net